[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4134 Introduced in House (IH)]
<DOC>
118th CONGRESS
1st Session
H. R. 4134
To amend the Federal Food, Drug, and Cosmetic Act to direct the
Secretary of Health and Human Services to establish a process to allow
the holders of abbreviated new drug applications to make labeling
changes to include new or updated safety-related information, and for
other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 14, 2023
Mr. Schiff (for himself and Ms. Kuster) introduced the following bill;
which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to direct the
Secretary of Health and Human Services to establish a process to allow
the holders of abbreviated new drug applications to make labeling
changes to include new or updated safety-related information, and for
other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Updated Drug Labeling for Patient
Safety Act''.
SEC. 2. SAFETY LABELING CHANGES INITIATED BY ANDA HOLDERS.
(a) In General.--Section 505(j) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(j)) is amended by adding at the end the
following:
``(14) Notwithstanding paragraph (2)(A)(v), the Secretary shall
establish a process to allow the holder of an abbreviated new drug
application to change the labeling of the drug that is the subject of
the application to include new or updated safety-related information,
including a process to make such changes prior to being approved by the
Secretary.''.
(b) Regulations.--
(1) In general.--Not later than 18 months after the date of
enactment of this Act, the Secretary of Health and Human
Services shall issue a final rule to implement paragraph (14)
of section 505(j) of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 355(j)), as added by subsection (a).
(2) Contents.--The final rule issued under paragraph (1)
shall include a process for conforming the labeling of a drug
that is labeled pursuant to such paragraph (14), the listed
drug (as such term is used in such section 505(j)), and other
drugs approved under such section 505(j) that reference such
listed drug.
(3) Effective date.--The final rule issued under paragraph
(1) shall become effective not later than 180 days after the
date on which such final rule is issued.
<all>